Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM (2017). Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. The Lancet Infectious Diseases 17(2):164-173.
Crossref

Bamba S, Séré A, Nikiéma R, Halidou T, Thiéba B, Dao B, Guiguemdé RT (2013). Traitement préventif intermittent à la sulfadoxine - pyriméthamine du paludisme chez les femmes enceintes: Efficacité et observance dans deux hôpitaux urbains du Burkina Faso. Pan African Medical Journal 14(1). 
Crossref

Boonyalai N, Thamnurak C, Sai P, Ta W, Gosi P, Utainnam D, Rodkvamtook W, Kuntawunginn W, Vesely BA, Spring MD, Fukuda MM, Lanteri C, Walsh D, Saunders DL, Smith PL, Wojnarski M, Sirisopana N, Waters NC, Jongsakul K, Gaywee J (2021). Plasmodium falciparum phenotypic and genotypic resistance profile during the emergence of Piperaquine resistance in Northeastern Thailand. Scientific Reports 11(1):1-13. 
Crossref

Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C, Woodrow CJ, Ashley EA, White NJ, Dondorp AM, Fairhurst RM, Ariey F, Menard D, Wirth DF, Volkman SK (2018). Plasmepsin II-III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nature communications 9(1):1-10. 
Crossref

Cheeseman IH, Gomez-Escobar N, Carret CK, Ivens A, Stewart LB, Tetteh KKA, Conway DJ (2009). Gene copy number variation throughout the Plasmodium falciparum genome. BMC Genomics 10(1):1-11. 
Crossref

Dhingra SK, Small-saunders JL, Ménard D, Fidock DA (2019). Plasmodium falciparum resistance to piperaquine driven by PfCRT The Lancet Infectious Diseases 19(11):1168-1169.
Crossref

Diallo MA, Yade MS, Ndiaye YD, Diallo I, Diongue K, Sy SA, Ndiaye D (2020). Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal. Scientific Reports 10(1):1-8. 
Crossref

Gupta H, Macete E, Bulo H, Salvador C, Warsame M, Carvalho E, Ménard D, Ringwald P, Bassat Q, Enosse S, Mayor A (2018). Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerging infectious diseases 24(1):40. 
Crossref

Hastings IM, Hodel EM, Kay K (2016). Quantifying the pharmacology of antimalarial drug combination therapy. Scientific Reports 6(1):1-7. 
Crossref

Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G, Ndong Ngomo JM, Varo R, Dossou Y, Tshefu AK, Duong TT, Phuc BQ, Laurijssens B, Klopper R, Khim N, Legrand E, Ménard D (2019). African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malaria Journal 18(1):1-11. 
Crossref

Mbaye A, Gaye A, Dieye B, Ndiaye YD, Bei AK, Affara M, Deme AB, Yade MS, Diongue K, Ndiaye IM, Ndiaye T, Sy M, Sy N, Koita O, Krogstad DJ, Volkman S, Nwakanma D, Ndiaye D (2017). (Plasmepsin II-III copy number accounts for bimodal piperaquine resistance amon. Malaria Journal 16:1-7. 
Crossref

Ministere de l'economie et des finances (2018). Rapport De L ' Etude Monographique Sur L ' Orpaillage Au.

Moss S, Ma?ko E, Krishna S, Campino S, Clark TG, Last A (2022). How has mass drug administration with dihydroartemisinin ? piperaquine impacted molecular markers of drug resistance?? A systematic review. Malaria Journal pp. 1-23. 
Crossref

PNLP-Senegal (2018). Bulletin Epidemiologique Annuel 2017 Du Paludisme Au Senegal Mars 40.

Russo G, L'Episcopia M, Menegon M, Souza SS, Dongho BGD, Vullo V, Lucchi NW, Severini C (2018). Dihydroartemisinin-piperaquine treatment failure in uncomplicated Plasmodium falciparum malaria case imported from Ethiopia. Infection 46:867-870.
Crossref

Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo AH, Koumare S, Keita M, Camara D, Somé AF, Coulibaly AS, Traore OB, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini ML, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore MJT, Ouattara SM, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma EC, Thera I, Compaore YD, Sutherland CJ, Sylla MM, Nikiema F, Diallo MS, Dicko A, Picot S, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Gil JP, Björkman A, Ouedraogo JB, Sirima SB, Djimde AA (2018). Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 391:1378-1390. 
Crossref

Sanogo K, Mårtensson A, Sagara I, Björkman A, Veiga MI, Ferreira, PE, Djimde A, Gil JP (2018). Plasmodium falciparum Plasmepsin 2 Duplications, West Africa 24:1591-1593.
Crossref

Saunders DL, Vanachayangkul P, Lon C (2014). Dihydroartemisinin-Piperaquine Failure in Cambodia. New England Journal of Medicine 371(5):484-485. 
Crossref

Thiam S, Thwing J, Diallo I, Fall FB, Diouf MB, Perry R, Ndiop M, Diouf, ML, Cisse MM, Diaw MM, Thior M (2012). Scale-up of home-based management of malaria based on rapid diagnostic tests and artemisinin-based combination therapy in a resource-poor country?: results in Senegal. Malaria Journal 11:1. 
Crossref

Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale JC, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariey F, Ménard D (2017). A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infectious Diseases 17(2):174-183. 
Crossref

World Health Organization (WHO) (2018). Artemisinin resistance and artemisinin-based combination therapy efficacy (Status report -- August 2018).